eligibility_summary
Adults ≥18 (US)/≥21 (SG), weight 40–100 kg (Parts A/B), ≤120 kg (others), advanced unresectable/metastatic solid tumor progressed with no SOC or intolerant, ECOG ≤2 (A), 0–1 (B–D), adequate hepatic/renal/bone marrow. Exclude: no tumor tissue, recent/ongoing anticancer or CSFs, strong P-gp/CYP3A drugs, E. coli/filgrastim allergy, brain mets, prior RT, recent surgery, pregnancy, corneal disease, active HIV/HBV/HCV. Pembrolizumab: active autoimmune, unresolved irAEs/steroids, ILD/pneumonitis, live vaccine <30d, prior ICI G2 myocarditis.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 1A/B open-label study in advanced solid tumors testing EBC-129 alone and with pembrolizumab. EBC-129 is an antibody–drug conjugate (ADC) targeting N-glycosylated CEACAM5/6, its tumor-targeting monoclonal antibody binds CEACAM5/6, is internalized, and releases monomethyl auristatin E (MMAE), a microtubule inhibitor causing mitotic arrest and cell death. The combination arm adds pembrolizumab, an anti–PD-1 immune checkpoint inhibitor that restores T-cell antitumor activity. Targets/pathways: CEACAM5/6-positive tumor cells, microtubule polymerization, PD-1/PD-L1 axis in the tumor microenvironment.